Adverum Biotechnologies Inc
ADVM2.440USD
+0.120+5.17%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
50.64MCap. mercado
PérdidaP/E TTM
Más Datos de Adverum Biotechnologies Inc Compañía
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Información de la empresa
Símbolo de cotizaciónADVM
Nombre de la empresaAdverum Biotechnologies Inc
Fecha de salida a bolsaJul 31, 2014
Director ejecutivoDr. Laurent Fischer, M.D.
Número de empleados155
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 31
Dirección100 Cardinal Way
CiudadREDWOOD CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94063
Teléfono16506491004
Sitio Webhttps://adverum.com/
Símbolo de cotizaciónADVM
Fecha de salida a bolsaJul 31, 2014
Director ejecutivoDr. Laurent Fischer, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Ms. Linda M. Rubinstein
Ms. Linda M. Rubinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason L. Mitchell
Mr. Jason L. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
Accionistas
Accionistas
Proporción
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
46.39%
Investment Advisor/Hedge Fund
15.91%
Individual Investor
12.20%
Private Equity
6.88%
Venture Capital
5.02%
Hedge Fund
2.57%
Research Firm
2.54%
Corporation
0.87%
Bank and Trust
0.12%
Other
7.51%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
192
19.32M
92.50%
-3.22M
2025Q1
200
18.99M
90.93%
-3.09M
2024Q4
197
18.17M
87.35%
-2.16M
2024Q3
205
18.40M
88.51%
-3.17M
2024Q2
198
18.25M
87.99%
-2.40M
2024Q1
209
17.03M
82.27%
+429.10K
2023Q4
203
6.60M
65.29%
-2.40M
2023Q3
243
6.95M
68.86%
-2.49M
2023Q2
271
6.98M
69.47%
-2.29M
2023Q1
309
6.72M
66.88%
-3.80M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BML Capital Management LLC
3.06M
14.64%
+315.21K
+11.49%
May 19, 2025
TCG Crossover Management, LLC
1.80M
8.6%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.76M
8.43%
--
--
Mar 31, 2025
Principia Wealth Advisory, LLC
1.70M
8.12%
+366.15K
+27.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.31M
6.29%
-57.92K
-4.22%
Mar 31, 2025
Stern (Augustus)
1.12M
5.35%
+1.12M
--
Oct 29, 2024
Frazier Life Sciences Management, L.P.
1.07M
5.12%
--
--
Mar 31, 2025
Rush (Ryan Bradford)
1.05M
5.03%
+1.05M
--
Dec 17, 2024
The Vanguard Group, Inc.
1.03M
4.93%
-1.76K
-0.17%
Mar 31, 2025
5AM Ventures
541.67K
2.59%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
Ver más
iShares Micro-Cap ETF
Proporción0.01%
Fidelity Enhanced Small Cap ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Fecha
Tipo
Relación
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
